24th Annual Cancer Progress Conference

During two days of presentations and panels, world-class researchers and key executives offer incisive overviews and candid assessments of today’s most important topics.

Unbiased cutting-edge presentations, lively panel discussions and vigorous audience interactions yield exceptional new understanding and insights. Networking is a major factor throughout the meeting during breaks, luncheons, reception and dinner.

Our 24th annual meeting, on March 5-6, 2013, again provided an unsurpassed learning experience with top marks from the participants for quality of information, coverage of issues, and value of professional contacts.
+ show speakers and program
Tuesday, March 5, 2013
7:00 – 8:00am Registration and Continental Breakfast
8:15 - 8:45am Opening Remarks
Jeff Bockman, PhD, Vice President, Defined Health
8:45 - 9:15am Keynote address: Pharmacoeconomics
Sir Michael Rawlins, MD, Chairman, NICE (Confirmed)
9:15 - 10:15am Translational Oncology
 Chris H. Takimoko, MD, PhD, Vice President,
Translational Medicine Early Development, Oncology
Therapeutic Area at Janssen, Pharmaceutical
Companies of Johnson and Johnson (Confirmed)
 J. Carl Barrett, PhD, Translational Sciences Onc iMed,
AstraZeneca (Confirmed)
 Perry Nisen, MD, PhD, Senior Vice President, Science &
Innovation, GlaxoSmithKline (Confirmed)
 Greg Plowman, MD, PhD Senior Vice President,
Research, ImClone Systems (Confirmed)
 Pamela Carroll, PhD, Nutley Oncology Discovery Site
Head & Global Head of Pathways Biology, Roche
Pharma Research and Early Development (pRED)
10:15 – 10:45am Networking Break
Cancer Progress LLC, c/o Defined Health, 25-B Hanover Road, Florham Park, NJ 07932
10:45 - 11:45pm Metabolism
 Tak Mak, PhD, Director, The Campbell Family Institute
for Breast Cancer Research, Ontario Cancer Institute;
University Professor, University of Toronto (Confirmed)
 Scott Biller, PhD, Chief Scientific Officer, Agios
Pharmaceuticals (Confirmed)
 Additional panelists TBA
11:45 - 12:45pm Next Generation Diagnostic Approaches: From Arrays to
Next Gen Sequencing
 Colin Hill, Chief Executive Officer President & Chairman,
GNS Healthcare (Confirmed)
 Michael J. Pellini, MD, President & Chief Executive
Officer, Foundation Medicine, Inc (Confirmed)
 Donald Bergstrom, MD, PhD, Head of Translational
Medicine, Oncology, Sanofi (Confirmed)
 Jay Flatley, President & CEO, Illumina, Inc (Invited)
 Jonathan M. Rothberg, PhD, Founder, 454 Life Sciences
 Randall Scott, PhD, Executive Chairman, Genomic
Health Inc. (Invited)
12:45 – 2:00pm Networking Luncheon
2:00 - 3:00pm Chemoprevention
Cancer Progress LLC, c/o Defined Health, 25-B Hanover Road, Florham Park, NJ 07932
 Michael B. Sporn, MD, Professor of Pharmacology,
Principal Investigator, Sporn Laboratory at Dartmouth
Medical School (Confirmed)
 Gary Kelloff, MD, Special Advisor, Division of Cancer
Treatment and Diagnosis, National Cancer Institute
 Raymond N. DuBois, Jr, MD, PhD, Provost & Executive
Vice President, The University of Texas MD Anderson
Cancer Center, Professor of Cancer Biology & Cancer
Medicine, The University of Texas MD Anderson Cancer
Center, Houston, TX (Invited)
 Scott M. Lippman, MD, Department Chair, Department of
Thoracic/Head and Neck Medical Oncology, Division of
Cancer Medicine, The University of Texas MD Anderson
Cancer Center (Invited)
 V. Craig Jordan, PhD, Scientific Director and Vice
Chairman of Oncology at the Lombardi Comprehensive
Cancer Center, Georgetown University (Invited)
3:00 - 3:30pm Networking Break
3:30 - 4:30pm Growing a Cancer-Focused Biotech: Learning from
Previous and Current Business Models
 Michael Morrissey, PhD, President & Chief Executive
Officer, Exelixis, Inc. (Confirmed)
 James S.J. Manuso, PhD, Chairman & Chief Executive
Officer, Astex Pharmaceuticals, Inc. (Confirmed)
 Patrick J. Mahaffy, President & Chief Executive Officer,
Clovis Oncology (Confirmed)
 Thomas O. Daniel, MD, President of Celgene Research
of Celgene Corporation (Invited)
 John Johnson, Chief Executive Officer, Dendreon
Corporation (Invited)
 Anthony Coles, MD, Chief Executive Officer, Onyx
Pharmaceuticals, Inc. (Invited)
4:30- 5:30pm Panel TBA
Cancer Progress LLC, c/o Defined Health, 25-B Hanover Road, Florham Park, NJ 07932
5:30-8:30pm Cancer Progress Reception
Wednesday, March 6, 2013
7:00 – 8:00am Continental Breakfast
8:00 - 8:15am Opening Remarks
Mike Rice, Senior Consultant, Defined Health
8:15 - 8:45am Keynote Address
Giulio Draetta, PhD, MD, Chief Research Business
Development Officer, MD Anderson Cancer Center
8:45 - 9:45am Stem Cell Panel
 George Q. Daley, MD, PhD, Samuel E. Lux, IV Professor
of Hematology, Director, Stem Cell Transplantation
Program, HHMI/Children’s Hospital Boston, Professor of
Biological Chemistry/Molecular Pharmacology and of
Pediatrics, Harvard Medical School, Brigham and
Women’s Hospital, Dana-Farber Cancer Institute,
Harvard Stem Cell Institute, Manton Center for Orphan
Disease Research (Confirmed)
 Christoph Westphal, MD, PhD, Chairman & Chief
Executive Officer, Verastem, Inc. (Confirmed)
 Jeremy Goldberg, President, JPG Healthcare LLC
 Takashi Owa, PhD, Vice President & Chief Innovation
Officer, Eisai (Confirmed)
9:45 - 10:15am Networking Break
10:15 - 11:15am Epigenetics – Are We There Yet? Building on the
Foundations of DNMT and HDAC Inhibitors
Cancer Progress LLC, c/o Defined Health, 25-B Hanover Road, Florham Park, NJ 07932
 Stephen B. Baylin, MD, Deputy Director of the Sidney
Kimmel Comprehensive Cancer Center at Johns
Hopkins, Virginia & D.K. Ludwig Professor in Cancer
Research, Associate Director of Cancer Center
Research, The Johns Hopkins University, School of
Medicine (Confirmed)
 Keith E. Dionne, PhD, President and Chief Executive
Officer, Constellation Pharmaceuticals (Confirmed)
 Robert J. Gould, PhD, Chief Executive Officer, Epizyme,
Inc. (Confirmed)
11:15 – 12:15pm Panel TBA
12:15 - 1:30pm Networking Luncheon
1:30 - 2:30pm AML Panel
Moderator: Leukemia & Lymphoma Society
 Brian J. Druker, MD, Director, OHSU Knight Cancer
Institute, JELD-WEN Chair of Leukemia Research,
Oregon Health & Science University, Investigator,
Howard Hughes Medical Institute (Confirmed)
2:30 – 3:00pm: Keynote Speaker TBA
3:00 – 3:30pm: Networking Break
3:30 - 4:45pm Next Generation Biologics for Cancer Therapy: Beyond
the Success of Conventional Monoclonal Antibodies
 Kirsten Drejer, PhD, Chief Executive Officer, Symphogen
A/S (Confirmed)
 Christian Zahnd, PhD, Chief Executive Officer, Molecular
Partners AG (Confirmed)

5 Mar - 6 Mar 2013
New York
United States of America
meeting website